Skip to main content
Fig. 2 | BMC Infectious Diseases

Fig. 2

From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Fig. 2

The transitions between the various classes of individuals, namely susceptible (S and \(S_{ij}\)), infected (I and \(I_{ij}\)) and removed (R and \(R_{ij}\)) when considering a two-dose vaccine program. SIR are unvaccinated and \(S_{ij},I_{ij},R_{ij}\) are vaccinated where i is the number of doses received and j is the type of vaccine

Back to article page